To further validate galectin-1 as a biomarker and to see if it could be utilized as a non-invasive peripheral blood biomarker of fibrosis, we investigated galectin-1 expression in a large cohort of 120 patients where platelet transcriptomes were available from patients with myelofibrosis (n=42), ET (n=24), PV (n=33) and healthy controls (n=21, Table S4) (38). The gene discussed is LGALS1; the disease is myelofibrosis.